The Committee on the Review of Medicines (CRM) followed its recent publication on the use of barbiturates1 2 with guidelines on the use of benzodiazepines in the treatment of anxiety and insomnia.3 These are intended to help manufacturers prepare their applications for revised product licences; they are not rigid recommendations. Modifications may still be agreed between manufacturers and the CRM. We first summarise the CRM’s findings and then comment on its recommendations.
Statistics from Altmetric.com
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.